The acellular pertussis vaccine trials: An interpretation

Pediatric Infectious Disease Journal

Volumn 16, Issue 5, 1997, Pages 508-519

  Plotkin, Stanley A ^a,b   Cadoz, Michel ^a  

^a Pasteur Merieux Connaught   (France)

^b NONE   (France)

Author keywords

acellular pertussis vaccines; efficacy trials; Pertussis whole cell vaccines

Indexed keywords

PERTUSSIS VACCINE;

CLINICAL TRIAL; DRUG RESEARCH; DRUG SCREENING; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; PERTUSSIS; PRIORITY JOURNAL; REVIEW; VACCINATION;

COHORT STUDIES; DOUBLE-BLIND METHOD; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MULTICENTER STUDIES; PERTUSSIS VACCINE; RANDOMIZED CONTROLLED TRIALS; VACCINES, INACTIVATED; WHOOPING COUGH;

EID: 0030920645     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199705000-00011     Document Type: Review

References (46)

1. Mortimer EA Jr. Pertussis vaccine. In: Plotkin SA, Mortimer EA Jr., eds. Vaccines. 2nd ed. Philadelphia: Saunders, 1994: 91-135.
2. Hinman AR. DTP vaccine litigation. Am J Dis Child 1986; 140:528-30.
3. Golden GS. Pertussis vaccine and injury to the brain. J Pediatr 1990;116:854-61.
4. Anonymous. Pertussis surveillance: United States, 1986-1988. MMWR 1990;39:57-9.
5. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia enhanced pertussis surveillance program. J Pediatr 1989;5:686-93.
6. Kimura M, Kuno-Sakai H. Developments in pertussis immunisation in Japan. Lancet 1990;1:30-2.
7. Aoyama T, Murase Y, Kato T, Iata T. Efficacy of an acellular pertussis vaccine in Japan. J Pediatr 1985;107:180-3.
8. Binkin NJ, Salmaso S, Tozzi AE, Scuderi G, Greco D. Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatr Infect Dis J 1992;11:653-61.
9. Ad hoc group for the study or pertussis vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet 1988;1:955-60.
10. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987;9:866-83.
11. Pittman M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough - a hypothesis. Rev Infect Dis 1979;1:401-12.
12. Robbins JB, Pittman M, Trollfors B, Lagergard TA, Taranger J. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J 1993;12:795-807.
13. Sato Y, Sato H, Izumiya K, Cowell JL, Manclark CR. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor hemagglutinin in immunity to pertussis. In: Robbins JB, Hill JC, eds. Seminars in infectious disease: bacterial vaccines. New York: Thieme-Stratton, 1981:380-5.
14. Robinson A, Sqworth LAE, Baskerville A, Irons LI. Protection against intranasal infection of mice with Bordetella pertussis. Proceedings of the Fourth International Symposium on Pertussis. Dev Biol Stand 1985;61:165-72.
15. Granström M, Olinder-Nielsen AM, Holmblad P, Mark A, Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet 1991;2:1230-3.
16. Sato Y, Izumiya K, Sato H, Cowell JL, Manclark CR. Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect Immun 1981;31:1223-31.
17. Novotny P, Chubb AP, Cownley K, Montaraz JA, Beesley JE. Bordetella adenylate cyclase: a genus specific protective antigen and virulence factor. Proceedings of the Fourth International Symposium on Pertussis. Dev Biol Stand 1985;61: 27-41.
18. Ashworth LAE, Irons LI, Dowsett AB. The antigenic relationship between serotype specific agglutinogens and fimbriae of Bordetella pertussis. Infect Immun 1982;37:1278-81.
19. Medical Research Council. Vaccination against whooping cough: final report. Br Med J 1959:994-1000.
20. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
21. Schmitt HJ, Von Konig CHW, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
22. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A placebo-controlled trial of a two and five component acellular and a US licensed whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
23. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
24. Liese JG, Harzer E, Meschievitz CK, et al. Case-control study to evaluate the efficacy of BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTacP) in infants [Abstract G83]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 18 to 20, 1995.
25. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind clinical trial comparing a 2-component acellular pertussis vaccine to a whole-cell vaccine in Senegal. Vaccine (in press).
26. Heininger U. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine, or DT vaccine. International Symposium on Pertussis Vaccine Trials, Rome, October 30 to November 1, 1995: trial synopses. Rome: Istituto Superiore di Sanità (in press).
27. Blackwelder WC, Storsaeter J, Olin P, Hallander HO. Acellular pertussis vaccines: efficacy and evaluation of clinical case definitions. Am J Dis Child 1991;145:1285-9.
28. Anonymous. WHO meeting on case definition of pertussis. WHO 1991:(MIN/EPJ/PERT/91.1):1-5.
29. Ishitobi A. Report of adverse reactions associated with new DTP vaccine available in Japan. J Child Health 1983;42:348-53.
30. Noble GR, Bernier RH, Esber EC, et al. Acellular and whole cell pertussis vaccines in Japan: report of a visit by US scientists. JAMA 1987;257:1351-6.
31. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66.
32. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995;96:548-57.
33. Olin P. Acellular pertussis vaccine trials: results and impact on U.S. public health [Abstract]. Presented at the National Institutes of Health Pertussis Conference, Washington, DC, June 3 to 5, 1996.
34. Storsaeter J, Hallander H, Farrington CP, Olin P, Mellby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990;8:457-61.
35. Gustafsson L, Hallander H, Olin P, Reizenstein E, Storsaeter J. Efficacy trial of acellular pertussis vaccines: Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity, 1995.
36. Storsaeter J, Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 1992;10:142-4.
37. Greco D, Salmaso S, Mastrantonio P, et al. A difference in relative efficacy of two DTaP vaccines in continued blinded observation of children following a clinical trial [Abstract]. Pediatr Res 1996;39:173A.
38. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA 1995;273: 1044-6.
39. Wiertz E, Walvoort H, van Loveren H, van Straaten I, van der Gun J, Kreeftenbert JG. Pertussis vaccines protect against the lethal effects of intracerebral challenge by two different -cell dependent humoral routes. Biologicals 1990;18:173-80.
40. Doebbeling BN, Feilmeirer ML, Herwaldt LA. Pertussis in an adult man infected with the human immunodeficiency virus. J Infect Dis 1990;161:1296-8.
41. Redhead K, Watkins J, Barnard A, Mills KH. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 1993;61:3190-8.
42. Mills KH, Redhead K. Cellular immunity in pertussis. J Med Microbiol 1993;39:163-4.
43. Steinhoff MC, Reed GF, Decker MD, et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 1995;96:567-70.
44. Edwards KM, Decker MD, Halsey NA, et al. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics 1991;88:1019-23.
45. Onorato IM, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 1992;267:2745-9.
46. Anonymous. Pertussis: United States, January 1992 to June 1995. MMWR 1995;44:525-9.